ArticleAmerican journal of translational research2025
Clinical efficacy of levofloxacin hydrochloride plus metronidazole in the treatment of pelvic inflammatory disease: a retrospective analysis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical efficacy and safety of levofloxacin (LEV) hydrochloride plus metronidazole (MNZ) in treating pelvic inflammatory disease (PID).
methodsThis retrospective study included 80 PID patients and grouped them based on their treatment regimens: a control group (n=40) treated with LEV hydrochloride injection and a research group (n=40) treated with MNZ plus LEV hydrochloride injection. Clinical efficacy, post-treatment inflammatory indexes, hemorheology (high-/low-shear viscosity [HSV/LSV], plasma viscosity [PV]), symptom resolution time, disease recurrence, as well as pre- and post-treatment pelvic mass diameter, pelvic effusion depth, and quality of life, were compared between the two groups. Adverse reactions during treatment and one-year recurrence were also recorded.
resultsCompared with the control group, the research group showed a significantly higher total clinical effective rate and faster clinical symptom resolution (including lower abdominal pain, abnormal leucorrhea, lumbosacral pain, urgent micturition, dysuria, and frequent micturition). Besides, the research group showed smaller pelvic mass diameter and pelvic effusion depth, superior quality of life, lower serum inflammatory markers, and reduced HSV, LSV, and PV levels. The one-year recurrence rate was also significantly lower in the research group.
conclusionsLEV hydrochloride combined with MNZ is both effective and safe for the treatment of PID, demonstrating notable advantages in promoting inflammation resolution, improving hemorheological parameters, reducing recurrence, and enhancing quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.